European Cancer Organisation

#EBCC10 NEWS: Statement on EPHOS-B (lapatinib/trastuzumab combination) trial

We wish to emphasise that our research has shown this treatment to be suitable for a group of women with a particular type of breast cancer. We have no evidence that it would be effective for anything other than patients with newly-diagnosed, HER2 positive breast tumours. In addition, we do not yet know what effect the treatment will have on long-term survival.
While we do not wish to downplay the significance of the findings, we also urge caution in their interpretation.  Further trials will be needed before we can confirm these results, even in HER2 positive patients.

Professor Judith Bliss
Professor Nigel  Bundred
Professor David Cameron
Lead researchers

Page last modified: